One last factor to consider, given the high percentage of hormone receptor-positive breast cancer patients [87], is the widespread prescription of AHT in the breast subgroup, which may influence the higher prevalence of SCNs in this subgroup. This evidence concerns the gene NR4A1 and breast carcinoma.